- Describing how a person should use a compound is what turns a research chemical into an unlicensed medicine in law. The disclaimer underneath doesn't undo it.
- A vendor who publishes protocols is telling you they either don't know the rule or have decided it doesn't apply to them — and that is the same person handling your cold chain.
- The literature is public. Trial protocols are on ClinicalTrials.gov and in the papers; we link them rather than paraphrase them.
- What we will answer, in detail: identity, purity, batch, storage, handling, delivery, and how to read every document we send you.
If you search the name of any compound we sell, the autocomplete fills in the rest: dosing, protocol, cycle, how much. Those are the questions most people bring to a site like this one, and this page exists to say plainly that we don't answer them — and why that is a feature of the business rather than a gap in it.
The line, in law
A research peptide is lawful to sell in the UK as a chemical for laboratory use. It becomes a medicinal product the moment it is presented as something to be administered to a person to modify a physiological function — and an unlicensed medicinal product may not be sold, supplied or advertised (regulations 46 and 279 of the Human Medicines Regulations 2012). We've set out the legal position separately.
"Presented" includes what the seller says. A page that describes how a person should take a compound, how often, at what dose and for how long, has presented it as a medicine. The words "for research use only" at the bottom of that page do not change what the page is. Regulators, courts and the advertising code all read the whole page.
So a dosing guide is not a customer service we've chosen to withhold. It is the one piece of content that would move the product from the lawful category to the unlawful one.
What it tells you about other vendors
Search results for these compounds are full of vendor pages with dosing tables, "beginner protocols" and week-by-week schedules under a research-use disclaimer. Read that as information about the vendor.
Either they do not understand the rule — in which case, consider what else in their operation is run on the same understanding — or they understand it and have decided the risk is worth the traffic. In both cases, the same judgement is being applied to the questions you can't see from a web page: where the material was actually made, whether the certificate matches the batch, and whether the parcel sat in a van in August.
The MHRA's 2025–26 operations against warehouses filling pens for public sale are the far end of that spectrum, but the spectrum is continuous, and a dosing table is the first visible step along it.
Where the real information is
None of this means the information doesn't exist. It means it exists in the right place.
- Clinical trial protocols are public. Every retatrutide and tirzepatide trial is registered on ClinicalTrials.gov with its design and dosing schedule, and the published papers report what was done. We link the papers in every compound article.
- Licensed medicines have labels. Tirzepatide is a licensed medicine in the UK (Mounjaro); its Summary of Product Characteristics is published by the MHRA and a prescriber can discuss it with you. That is the route for a person who wants to use tirzepatide.
- The literature on the others — BPC-157, TB-500, GHK-Cu — is preclinical, which is precisely why there is nothing to guide a person with. We say so in the articles.
A research supplier's job is to make sure that what arrives in the laboratory is what the label says, at the purity the certificate says, having been kept cold. That job is large enough.
What we will help with — in detail
Ask us anything in these categories and you'll get a straight answer, usually within the hour on chat:
- Identity and purity. What the certificate for your batch says, how to read it, and why the manufacturer's number and the independent lab's number differ slightly.
- Batch and traceability. Which batch you'd receive, its test date, and how to check it against the testing page.
- Storage and handling. Temperature, light, freezing, in-use limits, and what to do if a parcel arrived warm.
- The format. Why a pen and not a vial, what's in the box, and the device's in-use window.
- Delivery, payment and returns. All written down in the policies, and we'll walk you through any of it.
What you'll get if you ask a dosing question is a polite pointer back to this page. It isn't personal, and it isn't hedging — it's the reason the rest of what we say can be trusted.
The short version
We sell research compounds to people who research. The site says what the compounds are, what's been studied, what's in the box and how it was tested. It does not say what to do with them, because the day it does, it stops being a research supplier. Everything supplied is for in-vitro laboratory research only.
Sources
Questions this article answers
Why won't Biovanta tell me how to use a peptide?
Because describing how a person should use a compound presents it as a medicine, and an unlicensed medicine may not be sold or advertised in the UK. Answering the question would move the product from lawful research supply to unlawful supply — for the buyer's order as much as for the business.
Where can I read the trial dosing for retatrutide or tirzepatide?
In the registered trial records on ClinicalTrials.gov and in the published papers, which we cite in each compound article. Tirzepatide is also a licensed UK medicine (Mounjaro) with a published Summary of Product Characteristics that a prescriber can discuss.
Is a vendor with a dosing guide a bad sign?
It tells you the vendor either doesn't know the rule that governs their business or has chosen to ignore it. Both are worth weighing when you decide whether to trust the same vendor's certificates and cold chain.
Want the certificate for a real batch?
Name a compound and we'll send the manufacturer's HPLC-MS certificate for the batch you would receive — before you order, no account needed.